Clonal Hematopoiesis of Indeterminate Potential Is Associated with Current Smoking Status and History of Exacerbation in Patients with Chronic Obstructive Pulmonary Disease
Tuberculosis and Respiratory Diseases · 01.07.2024 · 87 (3) · 309-318
DOI: 10.4046/trd.2023.0165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tuberculosis and Respiratory Diseases, erschienen am 01.07.2024. Verfasst von Jung-Kyu Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Me…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: COPD
Abstract (Originalsprache)
Background
There is limited data regarding the clinical outcomes of clonal hematopoiesis of indeterminate potential (CHIP) in patients with chronic obstructive pulmonary disease (COPD). This study aimed to evaluate the clinical significance of CHIP as a COPD biomarker.
Methods
This retrospective study was conducted on patients with COPD who were enrolled prospectively in the Seoul National University Hospital Airway Registry from January 2013 to December 2019 and underwent pulmonary function and blood tests. We evaluated the CHIP score according to smoking status and severity of airflow obstruction.
Results
We analyzed next-generation sequencing data to detect CHIP in 125 patients with COPD. Current smokers had a higher prevalence of CHIP in combination of DNMT3A, TET2, and PPM1D (DTP), DNA methyltransferase 3 alpha (DNMT3A), and protein phosphatase, Mg2+/Mn2+ dependent 1D (PPM1D) genes than in never- or ex-smokers. CHIP of DTP and DNMT3A genes was significantly associated with current smokers (adjusted odds ratio [aOR], 2.80; 95% confidence interval [CI], 1.01 to 7.79) (aOR, 4.03; 95% CI, 1.09 to 14.0). Patients with moderate-to-severe airflow obstruction had a higher prevalence of CHIP in most of the explored genes than those with mild obstruction, although the difference was not statistically significant. CHIP in ASXL transcriptional regulator 1 (ASXL1) genes was significantly associated with history of mild, severe, and total acute exacerbation.
Conclusion
Given that CHIP in specific genes was significantly associated with current smoking status and acute exacerbation, CHIP can be considered as a candidate biomarker for COPD patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
- Genome Opinion. Inc. Seoul, Republic of Korea.
- Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Zitieren
APA
Lee, J. K., An, H., Koh, Y., & Lee, C. H. (2024). Clonal Hematopoiesis of Indeterminate Potential Is Associated with Current Smoking Status and History of Exacerbation in Patients with Chronic Obstructive Pulmonary Disease. Tuberculosis and Respiratory Diseases, 87(3), 309-318. https://doi.org/10.4046/trd.2023.0165
Vancouver
Lee JK, An H, Koh Y, Lee CH. Clonal Hematopoiesis of Indeterminate Potential Is Associated with Current Smoking Status and History of Exacerbation in Patients with Chronic Obstructive Pulmonary Disease. Tuberculosis and Respiratory Diseases. 2024;87(3):309-318. doi:10.4046/trd.2023.0165
BibTeX
@article{Lee2024,
author = {Lee, Jung-Kyu and An, Hongyul and Koh, Youngil and Lee, Chang-Hoon},
title = {Clonal Hematopoiesis of Indeterminate Potential Is Associated with Current Smoking Status and History of Exacerbation in Patients with Chronic Obstructive Pulmonary Disease},
journal = {Tuberculosis and Respiratory Diseases},
year = {2024},
volume = {87},
number = {3},
pages = {309--318},
doi = {10.4046/trd.2023.0165}
}
EUVIMED